Semax Improves Lipid Metabolism in Psoriasis Patients with Metabolic Syndrome

Patients suffering from psoriasis, a chronic inflammatory skin condition, frequently experience metabolic syndrome (MS), a cluster of risk factors including dyslipidemia (abnormal lipid levels). These lipid disturbances, such as high total cholesterol, triglycerides, and LDL cholesterol (often called 'bad' cholesterol), and low HDL cholesterol ('good' cholesterol), significantly increase the risk of cardiovascular disease in psoriasis patients. This study aimed to investigate whether adding semax to conventional therapy could correct these lipid metabolism disturbances in patients with both psoriasis and metabolic syndrome.

The study revealed a significant positive impact of semax on lipid profiles in the treatment group. Patients receiving semax showed a notable decrease in their initially elevated serum levels of total cholesterol, triglycerides, and LDL cholesterol. Simultaneously, there was an observed increase in their initially reduced HDL cholesterol levels. > In stark contrast, the group receiving only standard treatment did not exhibit any statistically significant effect on the levels of total cholesterol, triglycerides, LDL cholesterol, or HDL cholesterol in their blood serum. This indicates that semax provided a distinct and measurable benefit in correcting lipid abnormalities compared to conventional therapy alone, demonstrating its potential as an adjunctive treatment.